Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day in New York on September 24, 2015, with a presentation starting at 11:00 a.m. EDT to discuss ARC-520, its candidate for the treatment of chronic hepatitis B infection. During the event, Arrowhead management and a panel of key opinion leaders will discuss results of the Heparc-2001 Phase 2a study and results of a nonclinical study conducted in 9 chimpanzees chronically infected with hepatitis B virus.

Guest speakers at the event include:

Robert G. Gish, M.D.
Medical Director, Hepatitis B Foundation
Clinical Professor of Medicine, University of Nevada, Las Vegas
Senior Medical Director, St. Joseph’s Hospital and Medical Center
Clinical Professor of Medicine (Consultant), Stanford Hospital and Medical Center

Stephen A. Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Head of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory
Director of WHO Collaborating Centre for Virus Reference and Research

Robert E. Lanford, PhD
Director of Southwest National Primate Research Center (SNPRC)
Scientist, Virology and Immunology and SNPRC, Texas BioMedical Research Institute (Original Source)

Shares of Arrowhead Research closed yesterday at $5.55. ARWR has a 1-year high of $16.99 and a 1-year low of $4.35. The stock’s 50-day moving average is $5.89 and its 200-day moving average is $6.72.

On the ratings front, RBC analyst Michael Yee maintained a Hold rating on ARWR, with a price target of $9, in a report issued on August 5. The current price target implies an upside of 62.2% from current levels. According to, Yee has a total average return of 5.7%, a 56.2% success rate, and is ranked #658 out of 3752 analysts.

Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company’s drug candidate ARC-520 is designed to treat chronic hepatitis B infection.